Sai Life Sciences Ltd

- Sai Life Sciences plans to fund its capex of around INR 700 crores for FY26 through a combination of internal accruals, debt, and remaining funds from the IPO process. - There is no specific mention of new equity fundraising; the company intends to utilize the IPO proceeds still available. - Debt repayment of INR 720 crores was completed as part of the IPO funds, significantly reducing leverage. - Lower interest costs are expected from FY26 due to this reduced leverage. - The company balances funding between internal cash flows and debt but has not announced plans for fresh equity issuance.

- For FY26, Sai Life Sciences plans capex of close to INR 700 crores. - Approximately INR 550 crores of this capex is currently planned based on existing visibility, primarily to support fiscal '27 growth. - INR 50 to 70 crores of capex is earmarked for new modalities including peptides, ADCs, and oligonucleotides. - The remaining balance capex will be triggered based on business visibility throughout the year. - Around 60% to 65% of capex will be directed toward manufacturing, and 35% toward R&D. - Maintenance capex is roughly INR 70 crores. - New manufacturing capacities came online in November and May, increasing capacity by about 30%. - Capex funding will come from internal accruals, debt, and residual IPO proceeds. - Investments aim to support pipeline scaling, process development, and expand discovery and manufacturing capabilities.

- Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period. - The company plans to achieve EBITDA margins of 28% to 30% within the next couple of years. - Revenue growth reflects strong momentum across CDMO and CRO businesses, supported by molecule pipeline scaling up and commercial product volume increases. - FY25 revenue grew 16% YoY, with FY26 expected to continue strong growth momentum and improve from 25% EBITDA margin in FY25 to 28%-30% in next 2 years. - Capex of about INR700 crores planned for FY26 focused 60-65% on manufacturing and 35% on R&D to support FY27 growth. - Supply chain shifts favoring India and expanded capacity by 30% expected to support volume growth. - The business remains cyclical with potential volatility, but balanced across discovery, development, and commercial segments to sustain growth.

- Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility. - EBITDA margin guidance is maintained at 28%-30% within the next couple of years. - Profit after tax (PAT) for FY25 showed a strong 105% year-on-year increase, supported by operating leverage and cost efficiencies. - Return on capital employed (ROCE) is targeted in the mid-to-high teen range as committed during the IPO. - The company anticipates increasing capacity utilization and improving operational performance, which support future margin expansion. - Capex investments of around INR 700 crores for FY26 aim to support growth beyond fiscal year 2027. - Earnings growth may be lumpy due to the cyclical nature of the CDMO industry and timing of commercial product launches.

- Sai Life Sciences sees strong visibility and increased client flow supporting growth despite a softer global CRDMO environment. (Page 15) - Demand is driven primarily by supply chain shifts and long-standing client relationships. (Page 15) - The company has observed significant traction in both process development and manufacturing with several molecules scaling up, which is fueling capex expansion. (Pages 9, 10, 15) - Current manufacturing capacity utilization is high (~67% in FY25) with a 30% capacity increase expected from new lines coming online between November and May. (Page 6) - The pipeline shows some molecules in late-phase commercial stages; however, exact commercial launch timings are uncertain and out of CDMO control. (Page 10) - While specific orderbook numbers are not disclosed, the company expresses confidence in sustained pipeline demand and visibility over the next year. (Pages 6, 9, 10, 15)